Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

Sheu Wayne H. -H.; Gantz Ira; Chen Menghui; Suryawanshi Shailaja; Mirza Arpana; Goldstein Barry J.; Kaufman Keith D.; Engel Samuel S.

首页> 外文期刊>Diabetes care >Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

【24h】

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

机译：Omarigliptin（MK-3102），一种每周一次的新型DPP-4抑制剂治疗2型糖尿病的安全性和有效性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

OBJECTIVE

机译：目的

著录项

来源
《Diabetes care》 |2015年第11期|共9页
作者
Sheu Wayne H. -H.; Gantz Ira; Chen Menghui; Suryawanshi Shailaja; Mirza Arpana; Goldstein Barry J.; Kaufman Keith D.; Engel Samuel S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes [J] . Sheu Wayne H. -H., Gantz Ira, Chen Menghui, Diabetes care . 2015,第11期

机译：Omarigliptin（MK-3102），一种每周一次的新型DPP-4抑制剂治疗2型糖尿病的安全性和有效性
2. Once-weekly oral antidiabetic agent and treatment satisfaction: Re: Handelsman Y, Lauring B, Gantz I, etal. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin 2017: published online 26 May 2017, doi: 10.1080/03007995.2017 [J] . Takahara Mitsuyoshi, Shiraiwa Toshihiko, Katakami Naoto, Current medical research and opinion . 2017,第11期

机译：每周口服抗糖尿病药物和治疗满意度：Re：Handelsman Y，Grain B，Gantz I，Eetal。在二甲双胍单疗法对二甲双胍单疗法对2型糖尿病患者中，评估Omarigliptin，曾经每周DPP-4抑制剂或Glimepiride的疗效和安全性。 Curr Med Res orig 2017：在线发布2017年5月26日，Doi：10.1080 / 03007995.2017
3. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin [J] . Seung-Hwan Lee, Ira Gantz, Elizabeth Round, BMC Endocrine Disorders . 2017,第1期

机译：一项随机，安慰剂对照的临床试验，评估了每周一次的DPP-4抑制剂奥格列汀在格列美脲和二甲双胍控制不足的2型糖尿病患者中的安全性和有效性
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Diabetes Self-Care Management Behaviors and Barriers to Diabetes Care among Patients with Mental Illness and Type 2 Diabetes, Compared to Those with Type 2 Diabetes Only [D] . Olumba, Appolonia Adaku. 2018

机译：糖尿病在精神疾病和2型糖尿病患者中患糖尿病护理的自我保健管理行为和障碍，与2型糖尿病的患者相比
6. A randomized placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin [O] . Seung-Hwan Lee, Ira Gantz, Elizabeth Round, 2017

机译：一项随机安慰剂对照的临床试验评估每周一次的DPP-4抑制剂奥格列汀的安全性和有效性该药物对格列美脲和二甲双胍控制不足的2型糖尿病患者
7. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes [O] . Wayne H.-H. Sheu, Ira Gantz, Menghui Chen, 2015

机译：Omarigliptin（MK-3102）的安全性和有效性，一种新的一次每周DPP-4抑制剂，用于治疗2型糖尿病患者

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅